SPRO

#4125
Spero Therapeutics, Inc. - Common Stock
1.2 0 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.20
1.20
Intervallo Annuale
1.08
3.08
Variazione giornaliera
-0.83%
Variazione Mensile
0.00%
Variazione di 6 mesi
-43.40%
Variazione Annuale
-41.18%
Chiusura Precedente
1.2 1
Open
1.2 0
Minimo
1.2 0
Massimo
1.2 0
Volume
8
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, 28 Aug 2026
Spero Therapeutics, Inc. current report, 28 August 2026
8-K
Current report, Q3 FY2026
Spero Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Spero Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Spero Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Spero Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Spero Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Spero Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Spero Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Spero Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Spero Therapeutics, Inc. current report, Q1 FY2026
8-K

Spero Therapeutics, Inc. current report, Q1 FY2020

Full document

Business Context and Reporting Period

Company: Spero Therapeutics, Inc. (SPRO)
Filing Type: Form 8-K (Current Report)
Date of Report: March 16, 2020
Reporting Period: Fourth quarter and full year ended December 31, 2019
Context: The filing serves to announce the issuance of a press release containing financial results for the specified period. The company is an emerging growth company.

Key Financial Metrics

The provided text is a cover sheet for the 8-K filing and does not contain specific financial data points. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not available in the source text:

  • Revenue
  • Profit/Loss
  • Cash Flow
  • Margins
  • Debt and Liquidity

Note: The filing text does not provide a clear value for any financial metric.

Material Changes

No material changes or comparative financial data are detailed in the provided text. The document solely confirms the announcement of results for the period ended December 31, 2019.

Guidance, Outlook, and Risks

Management Commentary: The filing states that results were announced via a press release on March 16, 2020.
Legal Disclaimer: The information in Item 2.02 and the accompanying press release is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933. It will not be incorporated by reference into other SEC filings.
Guidance/Risks: No specific guidance, outlook, or risk factors are listed in the provided text.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release dated March 16, 2020) for actual revenue, net loss, and cash position figures.
  • Verify the company's cash runway and burn rate given the biotech sector context, as these are not in the 8-K cover text.
  • Confirm the status of the company's clinical trials and pipeline progress mentioned in the referenced press release.
  • Check for any subsequent filings regarding capital raises or liquidity events following this announcement.

Notizie